Healthcare Stocks to Watch: argenx, ICON, and Edwards Lifesciences with Long-Term Potential

Three healthcare stocks with long-term tailwinds include argenx SE, ICON plc, and Edwards Lifesciences Corp. Argenx develops treatments for autoimmune diseases using a unique antibody fragment therapy approach, while ICON is a contract research organization offering outsourced development and commercialization services. Edwards Lifesciences Corp. is a medical device manufacturer. All three companies have strong growth potential due to their innovative approaches and resilient revenue streams.

Three healthcare stocks with strong long-term growth prospects are Argenx SE, ICON plc, and Edwards Lifesciences Corp. Each of these companies offers unique value propositions and innovative approaches that position them for sustained growth.

Argenx SE
Argenx SE, a biotechnology company, specializes in developing treatments for autoimmune diseases using a unique antibody fragment therapy approach. The company has recently reported robust earnings for the second quarter of 2025, with earnings per share (EPS) of $6.32, significantly exceeding market expectations of $3.06 [1]. Revenue also surged to $1.74 billion, surpassing anticipated $876.3 million [1]. The strong consensus among analysts, including Jefferies analyst Akash Tewari who maintained a Buy rating with a $808 price target, reflects the company's impressive financial performance and promising pipeline [4]. The latest clinical trial results for Argenx's Vyvgart treatment have been particularly encouraging, positioning the company to file a supplemental biologics license application (sBLA) by the end of 2025 [3].

ICON plc
ICON plc is a global leader in the contract research organization (CRO) industry, offering comprehensive drug and device development services. Following its transformative acquisition of PRA Health Sciences, ICON boasts immense scale and a fully integrated service offering for its pharma and biotech clients [2]. The company's strategy focuses on delivering patient-centric and decentralized clinical trials, leveraging technology to improve access and efficiency. This approach aligns well with the growing trend of decentralized clinical trials, driven by factors such as the COVID-19 pandemic and advancements in digital technologies [2].

Edwards Lifesciences Corp.
Edwards Lifesciences Corp. is a medical device manufacturer known for its innovative cardiovascular and respiratory products. The company's strong revenue streams and resilient market position make it an attractive investment. Edwards Lifesciences Corp. benefits from the increasing prevalence of chronic diseases and the growing demand for advanced medical technologies [2].

Conclusion
Argenx SE, ICON plc, and Edwards Lifesciences Corp. each possess unique strengths and growth opportunities. Argenx's innovative antibody fragment therapy, ICON's leadership in decentralized clinical trials, and Edwards Lifesciences Corp.'s strong medical device portfolio position these companies for sustained growth. Investors should closely monitor these companies' developments and financial performance to capitalize on their long-term tailwinds.

References:
[1] https://www.investing.com/news/company-news/argenx-stock-reaches-alltime-high-at-69694-usd-93CH-4209141
[2] https://www.theglobeandmail.com/investing/markets/stocks/ARGX/pressreleases/34407855/oppenheimer-reaffirms-their-buy-rating-on-argenx-se-argx/
[3] https://www.investing.com/news/analyst-ratings/piper-sandler-raises-argenx-stock-price-target-to-820-on-vyvgart-success-93CH-4210933
[4] https://www.investing.com/news/rbc-capital-initiates-coverage-argenx-outperform-rating-pt-850-2508/